Oncolytics Biotech (ONCY) Operating Expenses (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Operating Expenses data on file, last reported at $10.1 million in Q3 2025.

• On a quarterly basis, Operating Expenses rose 38.59% year-over-year to $10.1 million in Q3 2025; TTM through Dec 2025 was $19.1 million, a 25.47% decrease from a year earlier, with the FY2025 full-year figure at $28.7 million, up 12.46% from the prior year.
• Operating Expenses for Q3 2025 stood at $10.1 million, up from $4.1 million in the prior quarter.
• Over the last five years, Operating Expenses for ONCY reached as high as $10.1 million in Q3 2025 and fell as low as $2.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $5.0 million across 5 years, with a median of $5.0 million in 2023.
• Across the five-year window, Operating Expenses soared 142.47% in 2023 and retreated 28.88% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $3.0 million in 2021, then jumped by 109.24% to $6.3 million in 2022, then grew by 3.7% to $6.5 million in 2023, then declined by 7.08% to $6.0 million in 2024, then soared by 66.51% to $10.1 million in 2025.
• Per Business Quant data, the three most recent Operating Expenses figures were $10.1 million in Q3 2025, $4.1 million in Q2 2025, and $4.9 million in Q1 2025.